Full Press Release Details
Supernus to Present at the Jefferies 2019 Global Healthcare Conference
ROCKVILLE, Md., May 29, 2019 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company s management will present a Company overview and update, as well as host investor meetings, at the Jefferies 2019 Global Healthcare Conference.
Date: Wednesday, June 5, 2019
Place: Grand Hyatt New York in New York City
Investors interested in arranging a meeting with the Company s management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investors section on the Company s website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company s website after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD, and SPN-604 for the treatment of bipolar disorder.
Jack A. Khattar, President and CEO
Gregory S. Patrick, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com